MADRID (Reuters) – Rovi has received non-binding offers for its third-party manufacturing business, the Spanish pharmaceuticals firm said on Wednesday, without disclosing the names of the bidders.
No final decision has been made regarding the potential sale, Rovi said in a filing to the stock market regulator.
Investment funds Antin, Cinven, CVC, KKR and Permira have filed bids, newspaper Expansion reported earlier on Wednesday.
The five firms filed non-binding bids on June 13 and are now in the middle of a due diligence process for binding offers, the newspaper reported.
Spokespeople for Cinven and KKR declined to comment, while Antin, CVC and Permira did not immediately respond to requests for comment.
Rovi said in March it had hired Lazard as an adviser for a potential sale of a business which has produced COVID-19 vaccines on behalf of Moderna, among other drugs.
It is estimated to be worth about 3.5 billion euros ($3.75 billion), Expansion said.
($1 = 0.9344 euros)
(Reporting by Inti Landauro and Joao Manuel Mauricio; editing by Jason Neely)
Comments